Posted on 4/15/19
Martin's Point Health Care Named One of the 2019 Best Workplaces in Health Care and Biopharma
Great Place to Work and FORTUNE have honored Martin's Point Health Care as one of the 2019 Best Workplaces in Health Care and Biopharma. The ranking . . .
Posted on 4/15/19
X4 Pharmaceuticals Prices $85.8M Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today . . .
Posted on 4/15/19
Peak Physical Therapy & Sports Performance Appoints Donna Chiao as Staff Physical Therapist
Peak Physical Therapy & Sports Performance, a South Shore practice specializing in unique programs that
Posted on 4/12/19
TransMedics Group Files For U.S. IPO
SummaryTransMedics has filed to raise $86.25 million in an IPO, although the final figure may be different.The company is commercializing an organ transplant care system in . . .
Posted on 4/12/19
Cara Therapeutics: Targeting CKD-Associated Pruritus
SummaryCara's KORSUVA is targeting pruritus in CKD patients undergoing dialysis.There are no approved drugs in the US using the MOA of KORSUVA.However, the market is quite . . .
Posted on 4/12/19
Trevi Therapeutics Begins IPO Process
SummaryTrevi Therapeutics has filed its initial S-1 registration statement for an IPO.The firm is developing treatment candidates for pruritus and other serious conditions.TRVI expects to publish . . .
Posted on 4/12/19
bluebird bio's CHMP Response Lays Groundwork For Its First Gene Therapy Approval
Summarybluebird bio's Zynteglo receives positive CHMP opinion for approval of Zynteglo to treat transfusion dependent beta-thalassemia patients.The European Commission is expected to make its final decision . . .
Posted on 4/11/19
Summit Health Management Partners with Arcadia.io
BERKELEY HEIGHTS, N.J. & BURLINGTON, Mass.--(BUSINESS WIRE)--Summit Health Management (SHM), which offers a physician-led, professionally-managed model of management services for Summit Medical Group in New Jersey . . .
Posted on 4/11/19
X4 Pharmaceuticals Proposes Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today . . .
Posted on 4/11/19
Intrinsic Therapeutics Completes $52M Financing
Intrinsic Therapeutics, Inc., a medical device company focusing on surgeries to treat leg and low back pain resulting from ruptured lumbar discs with large anular defects
Posted on 4/11/19
Sonde Completes $16 Million Series A Financing
Sonde Health Inc., a company developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions
Posted on 4/11/19
AskBio Lands $235M Financing From TPG And Vida Ventures
Asklepios BioPharmaceutical, Inc (AskBio), a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for underserved patient populations
Posted on 4/10/19
Provident Healthcare Partners Advises Southeast Gastro In Its Partnership With Gastro Health
Southeast Gastro, a Birmingham Alabama-based gastroenterology practice with 20 board-certified gastroenterologists, 17 advanced practitioners, 8 locations, and three surgery centers, has partnered with Gastro Health, a . . .
Posted on 4/10/19
Curis Regains Compliance with Nasdaq Continued Listing Requirements
Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation . . .
Posted on 4/10/19
Inozyme Pharma Raises $67 Million in Series A2 Financing
Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders
Posted on 4/10/19
Why bluebird bio Could Deliver Miracles to Genetic Disease Patients
Over the course of The Motley Fool's 26-year history, one of its guiding principles has been to look for the positive side of the story. The . . .
Posted on 4/10/19
Biogen Alzheimer's Failure Is Not Surprising, More Will Follow
SummaryBiogen’s Alzheimer’s aducanumab failure heaps on more evidence that beta amyloid plaque is an effect of Alzheimer’s rather than the cause.Other companies pursuing the beta amyloid . . .
Posted on 4/10/19
Berkshire Hathaway's True Moat
SummaryA brand moat in the consumer space is difficult to sustain today.Berkshire Hathaway still has exposure to some wonderful businesses.The $100 billion cash pile is where . . .
Posted on 4/10/19
Why Vertex Pharmaceuticals Could Conceivably Succeed Too Well
Over the course of The Motley Fool's 26-year history, one of its guiding principles has been to look for the positive side of the story. The . . .
Posted on 4/10/19
Syros Closes Concurrent Public Offerings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its previously . . .
Posted on 4/10/19
Homology Medicines Prices Public Offering of Common Stock
BEDFORD, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, today announced the pricing of an underwritten public offering . . .
Posted on 4/10/19
AquaBounty Technologies Closes Public Offering of Common Stock
MAYNARD, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq: AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a . . .
Posted on 4/9/19
Diameter Health Announces $9.6 Million in Series A-1 Funding Round
Diameter Health, a market leader in clinical data integration, today announced a $9.6 million Series A-1 funding round.
Posted on 4/9/19
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
ZURICH & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of . . .
Posted on 4/9/19
Charles River Laboratories and CHDI Foundation Extend Huntington’s Disease Collaboration
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation today announced a five-year extension of their ongoing collaboration. The organizations began working together . . .

